NCT07270211Not yet recruiting
MCG In Long QT Syndrome
Magnetocardiography in Long QT Syndrome: A Prospective Study of Its Clinical and Prognostic Utility
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The primary objective of this observational study is to evaluate whether magnetocardiography (MCG) findings more accurately predict clinical outcomes in patients with acquired Long QT syndrome compared to ECG. The secondary objective is to assess differences in QT interval length between MCG and ECG. The primary safety objective is to characterize the safety profile of the CardiAQ MCG device.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 25 Nov 2025
- Start date
- Sept 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Atrial fibrillation
- NCT number
- NCT07270211
What you commit to
- Study type: Observational
- Planned participants: 100
- From Sept 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillators).
- External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
- Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol
Other
- Pregnant or breastfeeding
- Inability to lie down in a supine/inclined position and stay still on the examination bed
Who the study is looking for
- Age ≥ 18 years on the date of consent
- Ability for participant to comply with study requirements
- Written informed consent
- Confirmed diagnosis of atrial fibrillation and receiving dofetilide for rhythm control in the inpatient setting.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.